What question did this study set out to answer?

To assess the long-term clinical efficacy and safety of gene therapy in correcting immunodeficiency in patients with SCID-X1.

July 21, 2010New England Journal of MedicineOpen Access

Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency

View Full Paper

Ask AI

Bookmark

Authors

SHSalima Hacein‐Bey‐AbinaCentre National de la Recherche Scientifique JHJulia HauerMünchen Klinik Schwabing ALApiradee LimPrince of Songkla University

Discussion

Member takes

Implication

Long-term follow-up study demonstrates sustained immune correction in SCID-X1 patients after gene therapy, indicating therapeutic efficacy despite leukemia risks.

Key Points

To assess the long-term clinical efficacy and safety of gene therapy in correcting immunodeficiency in patients with SCID-X1.
Monitored patients with SCID-X1 who received gene therapy across nearly 10 years of follow-up.
Evaluated clinical utility specifically for individuals lacking an HLA-identical donor for hematopoietic stem-cell transplantation.
Gene therapy corrected the severe immunodeficiency associated with SCID-X1 over nearly a decade of follow-up.
Treatment was associated with a documented risk of developing acute leukemia.

Cite This Study

Hacein‐Bey‐Abina et al. (2010) studied this question.

synapsesocial.com/papers/69d73de73f2a6ac123b8adef https://doi.org/10.1056/nejmoa1000164

View Full Paper

Ask AI

Bookmark

Implication

Long-term follow-up study demonstrates sustained immune correction in SCID-X1 patients after gene therapy, indicating therapeutic efficacy despite leukemia risks.

Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider